Signaturefd, LLC Intra Cellular Therapies, Inc. Transaction History

Signaturefd, LLC

$5.2 Billion
Q3 2024

A detailed history of Signaturefd, LLC transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Signaturefd, LLC holds 538 shares of ITCI stock, worth $46,499. This represents 0.0% of its overall portfolio holdings.

Number of Shares

538

Previous 530 1.51%

Holding current value

$46,499

Previous $36,000 8.33%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 21, 2024	BUY	$67.99 - $80.84 $543 - $646	8 Added 1.51%	538 $39,000
Q2 2024 Jul 29, 2024	BUY	$64.76 - $79.84 $3,497 - $4,311	54 Added 11.34%	530 $36,000
Q1 2024 May 03, 2024	SELL	$64.37 - $75.65 $2,703 - $3,177	-42 Reduced 8.11%	476 $32,000
Q4 2023 Jan 31, 2024	BUY	$46.37 - $73.65 $11,082 - $17,602	239 Added 85.66%	518 $37,000
Q3 2023 Nov 03, 2023	SELL	$52.09 - $64.1 $3,698 - $4,551	-71 Reduced 20.29%	279 $14,000
Q2 2023 Aug 01, 2023	BUY	$54.67 - $66.44 $3,280 - $3,986	60 Added 20.69%	350 $22,000
Q1 2023 Apr 28, 2023	BUY	$43.8 - $56.99 $963 - $1,253	22 Added 8.21%	290 $15,000
Q4 2022 Jan 27, 2023	BUY	$44.07 - $54.45 $5,640 - $6,969	128 Added 91.43%	268 $14,000
Q3 2022 Nov 08, 2022	BUY	$42.7 - $59.99 $2,305 - $3,239	54 Added 62.79%	140 $7,000
Q2 2022 Aug 10, 2022	SELL	$43.0 - $65.64 $6,665 - $10,174	-155 Reduced 64.32%	86 $5,000
Q1 2022 May 02, 2022	BUY	$38.74 - $62.09 $5,462 - $8,754	141 Added 141.0%	241 $15,000
Q4 2021 Jan 25, 2022	BUY	$35.2 - $53.42 $1,196 - $1,816	34 Added 51.52%	100 $5,000
Q3 2021 Oct 28, 2021	SELL	$28.72 - $42.49 $258 - $382	-9 Reduced 12.0%	66 $2,000
Q2 2021 Jul 26, 2021	BUY	$29.3 - $44.5 $1,318 - $2,002	45 Added 150.0%	75 $3,000
Q1 2021 Apr 30, 2021	BUY	$30.8 - $39.51 $924 - $1,185	30 New	30 $1,000

Others Institutions Holding ITCI

# of Institutions

378

Shares Held

84.7M

Call Options Held

319K

Put Options Held

143K

View Full List

About Intra-Cellular Therapies, Inc.

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $8.16B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

More about ITCI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Signaturefd, LLC with notifications on news.

Account